US20210190769A1 - Distinguishing cancer from neurological risk using copy number variation - Google Patents
Distinguishing cancer from neurological risk using copy number variation Download PDFInfo
- Publication number
- US20210190769A1 US20210190769A1 US17/128,446 US202017128446A US2021190769A1 US 20210190769 A1 US20210190769 A1 US 20210190769A1 US 202017128446 A US202017128446 A US 202017128446A US 2021190769 A1 US2021190769 A1 US 2021190769A1
- Authority
- US
- United States
- Prior art keywords
- pten
- copy number
- number variation
- subject
- germline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 56
- 201000011510 cancer Diseases 0.000 title claims description 47
- 230000000926 neurological effect Effects 0.000 title description 2
- 230000035772 mutation Effects 0.000 claims abstract description 85
- 210000004602 germ cell Anatomy 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 44
- 238000012217 deletion Methods 0.000 claims abstract description 37
- 230000037430 deletion Effects 0.000 claims abstract description 37
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims abstract description 36
- 238000004458 analytical method Methods 0.000 claims abstract description 35
- 239000012472 biological sample Substances 0.000 claims abstract description 26
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 19
- 238000003745 diagnosis Methods 0.000 claims abstract description 16
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims abstract description 11
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims abstract description 11
- 208000029560 autism spectrum disease Diseases 0.000 claims description 87
- 230000001717 pathogenic effect Effects 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 16
- 238000003908 quality control method Methods 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 claims description 5
- 238000007480 sanger sequencing Methods 0.000 claims description 5
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims description 4
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 claims description 4
- 238000011880 melting curve analysis Methods 0.000 claims description 4
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 76
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 76
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 description 64
- 206010012559 Developmental delay Diseases 0.000 description 55
- 201000010917 PTEN hamartoma tumor syndrome Diseases 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 37
- 108090000623 proteins and genes Proteins 0.000 description 36
- 201000010099 disease Diseases 0.000 description 28
- 208000012609 Cowden disease Diseases 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 201000002847 Cowden syndrome Diseases 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 102100038417 Cytoplasmic FMR1-interacting protein 1 Human genes 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 101000956872 Homo sapiens Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 208000020706 Autistic disease Diseases 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 206010050183 Macrocephaly Diseases 0.000 description 5
- 208000005767 Megalencephaly Diseases 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- 238000013517 stratification Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 206010003805 Autism Diseases 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101150073900 PTEN gene Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000003723 learning disability Diseases 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000035976 Developmental Disabilities Diseases 0.000 description 3
- 208000002927 Hamartoma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 208000036626 Mental retardation Diseases 0.000 description 3
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 description 3
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 3
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 208000036640 Asperger disease Diseases 0.000 description 2
- 201000006062 Asperger syndrome Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000016311 Freckling Diseases 0.000 description 2
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 description 2
- 101000874160 Homo sapiens Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Proteins 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 2
- 108091029795 Intergenic region Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 2
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 2
- 102100035726 Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial Human genes 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008482 dysregulation Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 235000011475 lollipops Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 208000017976 8p23.1 duplication syndrome Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006256 Breast hyperplasia Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000027691 Conduct disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 101710181791 Cytoplasmic FMR1-interacting protein 1 Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 1
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 1
- 102100022197 Glutamate receptor ionotropic, kainate 1 Human genes 0.000 description 1
- 101710112359 Glutamate receptor ionotropic, kainate 1 Proteins 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 101000951145 Homo sapiens Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 208000022010 Lhermitte-Duclos disease Diseases 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012266 Needlestick injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000027626 Neurocognitive disease Diseases 0.000 description 1
- 208000019739 Neurodevelopmental delay Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000016012 Phenotypic abnormality Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100038014 Succinate dehydrogenase [ubiquinone] cytochrome b small subunit, mitochondrial Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000009453 Thyroid Nodule Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000007844 allele-specific PCR Methods 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 201000007741 female breast cancer Diseases 0.000 description 1
- 201000002276 female breast carcinoma Diseases 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000037442 genomic alteration Effects 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000021991 hereditary neoplastic syndrome Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000029209 intraductal breast papilloma Diseases 0.000 description 1
- 201000008632 juvenile polyposis syndrome Diseases 0.000 description 1
- 206010024217 lentigo Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000008271 nervous system development Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001123 neurodevelopmental effect Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000001558 permutation test Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000013138 pruning Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000007420 thrombocytopenia-absent radius syndrome Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Definitions
- PTEN germline mutations include mutations of the phosphatase and tensin homolog (PTEN) gene (UCSC ID, uc001kfb.2; RefSeq, NM_000314), encoding deletions on chromosome 10. PTEN germline mutations are among the most common causes of autism spectrum disorder (ASD), accounting for approximately 2% to 5% of cases (Butler et al., J Med Genet., 42(4): 318-321 (2005)), yet originally identified in a subset of relatively rare syndromes predisposing to breast, thyroid, and other cancers. Liaw et al., Nat Genet., 16(1):64-67 (1997).
- the concept of PTEN hamartoma tumor syndrome (PHTS) was proposed to encompass any clinical disorder with germline PTEN mutation on molecular genetic testing, regardless of phenotype. Marsh et al., Hum Mol Genet., 8(8):1461-1472 (1999). Based on this broad clinical spectrum and unified genetic etiology, PHTS serves as a useful disease model to identify modifiers of variable heritable disease risk at the individual level.
- Copy number variation (CNV), a common type of structural variation in the human genome, is considered an important contributor to non-syndromic idiopathic ASD and sporadic cancer.
- CNV Copy number variation
- Jeste S S Geschwind D H., Nat Rev Neurol., 10(2):74-81 (2014); Huang et al; Cell, 173(2):355-370.e14 (2016).
- Copy number variations have also been associated with complex disorders, particularly those involving developmental delay, intellectual disabilities, and/or congenital anomalies. Miller et al., Am J Hum Genet., 86(5):749-764 (2010).
- the present invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations.
- the method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.
- a copy number variation level that is higher than the control value indicates a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer.
- the neurodevelopmental disorder is autism spectrum disorder.
- the genomic DNA comprises the PTEN promoter region.
- the deletion analysis is conducted using a multiplex ligation-dependent probe amplification assay.
- the mutation analysis comprises denaturing gradient gel electrophoresis, high-resolution melting curve analysis, and directed Sanger sequencing.
- the step of determining the level of copy number variation comprises single-nucleotide polymorphism genotype quality control.
- the subject has Cowden-like syndrome. In further embodiments, the subject has PTEN germline mutations. In yet further embodiments, the germline PTEN mutations are pathogenic germline PTEN mutations.
- the inventors conducted a prospective cohort study that examined genome-wide microarrays performed on blood-derived DNA to detect germline CNVs from participants, including patients with PTEN hamartoma tumor syndrome (PHTS), molecularly defined as carrying germline pathogenic PTEN mutations.
- PHTS PTEN hamartoma tumor syndrome
- FIGS. 1A and 1B provide graphs showing (A) Genome-wide CNV burden representing the total number of CNVs in each patient within the 3 PHTS phenotype groups.
- the line in the middle of each box is plotted at the median.
- Each box extends from the 25th to 75th percentiles (interquartile range [IQR]). Whiskers and outliers (circles) are plotted according to the Tukey method. The upper whiskers extend to the largest value no further than 1.5 times the IQR.
- the lower whiskers extend to the smallest value no further than 1.5 times the IQR;
- B Stratified analyses showing CNV burden (duplications and deletions) in genic and nongenic genomic regions, accounted for by the number of unrelated patients carrying such CNVs within each clinical phenotype group. The size of each box is proportional to the respective odds ratio (OR) depicted in the adjacent table.
- ASD indicates autism spectrum disorder; DD, developmental delay.
- FIG. 2 provides a graph showing pathogenic and/or likely pathogenic CNVs associated with neurodevelopmental disorders were found in 11 of 110 patients in the ASD/DD group (10.0%), 5 of 194 patients in the no ASD/DD group (2.6%), and 2 of 121 patients in the subgroup with cancer (1.7%).
- the size of each box is proportional to the respective odds ratio (OR) depicted in the adjacent table.
- FIGS. 3A-3C provides graphs showing PTEN mutation spectra across the PHTS Clinical Phenotype Groups. PTEN mutations are depicted in the lollipop plots overlying the PTEN protein structures. The frequency of each mutation correlates with the heights of the vertical lines representing each lollipop.
- A PTEN mutations identified in PHTS individuals with autism spectrum disorder/developmental delay (ASD/DD). Three whole PTEN gene deletions, one exon 1 deletion, and one exon 1 duplication are not depicted.
- B PTEN mutations identified in PHTS individuals without ASD/DD, including the subset with cancer.
- the present invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations.
- the method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.
- diagnosis can encompass determining the likelihood that a subject will develop a disease, or the existence or nature of disease in a subject.
- diagnosis also encompasses determining the severity and probable outcome of disease or episode of disease or prospect of recovery, which is generally referred to as prognosis).
- prognosis can also encompass diagnosis in the context of rational therapy, in which the diagnosis guides therapy, including initial selection of therapy, modification of therapy (e.g., adjustment of dose or dosage regimen), and the like.
- treatment refers to obtaining a desired pharmacologic or physiologic effect.
- the effect may be therapeutic in terms of a partial or complete cure for a disease or an adverse effect attributable to the disease.
- Treatment covers any treatment of a disease in a mammal, particularly in a human, and can include inhibiting the disease or condition, i.e., arresting its development; and relieving the disease, i.e., causing regression of the disease.
- Prevention or prophylaxis refers to preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease). Prevention may include completely or partially preventing a disease or symptom.
- nucleic acid molecule refers to a polymeric form of nucleotides of at least 10 bases in length.
- the term includes DNA molecules (e.g., cDNA or genomic or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as analogs of DNA or RNA containing non-natural nucleotide analogs, non-native inter-nucleoside bonds, or both.
- the nucleic acid can be in any topological conformation. For instance, the nucleic acid can be single-stranded, double-stranded, triple-stranded, quadruplexed, partially double-stranded, branched, hair-pinned, circular, or in a padlocked conformation.
- gene refers to a nucleotide sequence that can direct synthesis of an enzyme or other polypeptide molecule (e.g., can comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a polypeptide) or can itself be functional in the organism.
- a gene in an organism can be clustered within an operon, as defined herein, wherein the operon is separated from other genes and/or operons by intergenic DNA. Individual genes contained within an operon can overlap without intergenic DNA between the individual genes.
- genotype refers to the alleles present in DNA from a subject or patient, where an allele can be defined by the particular nucleotide(s) present in a nucleic acid sequence at a particular site(s). Often a genotype is the nucleotide(s) present at a single polymorphic site known to vary in the human population.
- a “germline mutation,” as used herein, refers to a heritable change in the DNA that occurred in a germ cell (a cell destined to become an egg or in the sperm) or the zygote (the conceptus) at the single-cell stage. When transmitted to a child, a germline mutation is incorporated in every cell of their body.
- Codon number variation revers to a number of genes that is different from the norm (which is typically two copies). Variation in the copy number is generally caused by deletion or duplication of genes.
- polymorphism refers to a difference in the nucleotide sequence of a given region as compared to a nucleotide sequence in a homologous region of another individual, in particular, a difference in the nucleotide sequence of a given region that differs between individuals of the same species. Polymorphisms include single nucleotide differences, differences in sequence of more than one nucleotide, insertions, inversions and deletions. The term refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population.
- a polymorphic marker is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%.
- a polymorphic locus can be as small as one base pair.
- the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ⁇ 20%, in some embodiments ⁇ 10%, in some embodiments ⁇ 5%, in some embodiments ⁇ 1%, in some embodiments ⁇ 0.5%, and in some embodiments ⁇ 0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
- One aspect of the invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations, the method comprising the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.
- a copy number variation level that is higher than the control value indicates a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer.
- the present invention provides methods for diagnosing subjects having an increased risk of developing a neurodevelopmental disorder.
- Neurodevelopmental disorders are disabilities associated primarily with the functioning of the neurological system and brain. Examples of neurodevelopmental disorders in children include attention-deficit/hyperactivity disorder (ADHD), autism, learning disabilities, intellectual disability (also known as mental retardation), conduct disorders, cerebral palsy, and impairments in vision and hearing.
- ADHD attention-deficit/hyperactivity disorder
- autism autism
- learning disabilities intellectual disability (also known as mental retardation)
- conduct disorders cerebral palsy
- impairments in vision and hearing a cognitive disability (or learning disorder) is a general term for a neurological disorder that affects the way in which a child's brain can receive, process, retain, and respond to information.
- Children with neurodevelopmental disorders can experience difficulties with language and speech, motor skills, behavior, memory, learning, or other neurological functions.
- the neurodevelopmental disorder is autism spectrum disorder.
- Autism spectrum disorders are a group of developmental disabilities defined by significant social, communication, and behavioral impairments.
- the term “spectrum disorders” refers to the fact that although people with ASDs share some common symptoms, ASDs affect different people in different ways, with some experiencing very mild symptoms and others experiencing severe symptoms.
- ASDs encompass autistic disorder and the generally less severe forms, Asperger's syndrome and pervasive developmental disorder-not otherwise specified (PDD-NOS). Children with ASDs may lack interest in other people, have trouble showing or talking about feelings, and avoid or resist physical contact.
- a range of communication problems are seen in children with ASDs: some speak very well, while many children with an ASD do not speak at all.
- ASDs Another hallmark characteristic of ASDs is the demonstration of restrictive or repetitive interests or behaviors, such as lining up toys, flapping hands, rocking his or her body, or spinning in circles. Examples of ASDs are autistic disorder, Asperger's disorder, and pervasive developmental disorder. McPartland, J., and Volkmar, F., Handb Clin Neurol, 106:407-18 (2012).
- the method of diagnosis includes the step of obtaining a biological sample from a subject.
- a “biological sample,” as used herein, is meant to include any biological sample from a subject that is suitable for detection and analysis of the copy number variation in the genomic DNA of the subject. Suitable biological samples include but are not limited to bodily fluids such as blood-related samples (e.g., whole blood, serum, plasma, and other blood-derived samples), urine, sputem, cerebral spinal fluid, bronchoalveolar lavage, and the like.
- Another example of a biological sample is a tissue sample.
- the biological sample is a cancer cell or tissue including cancer cells.
- the copy number variation in the genomic DNA of the subject can be assessed either quantitatively or qualitatively, and detection can be conducted either in vitro or ex vivo.
- the methods involve providing or obtaining a biological sample from the subject, which can be obtained by any known means including needle stick, needle biopsy, swab, and the like.
- the biological sample is a blood sample, which may be obtained for example by venipuncture.
- a biological sample may be fresh or stored.
- Biological samples may be or have been stored or banked under suitable tissue storage conditions.
- the biological sample may be a tissue sample expressly obtained for the assays of this invention or a tissue sample obtained for another purpose which can be subsampled for the assays of this invention.
- tissue samples are either chilled or frozen shortly after collection if they are being stored to prevent deterioration of the sample.
- the sample may be pretreated as necessary by dilution in an appropriate buffer solution, heparinized, concentrated if desired, or fractionated by any number of methods including but not limited to ultracentrifugation, fractionation by fast performance liquid chromatography (FPLC) or HPLC, or precipitation of apolipoprotein B containing proteins with dextran sulfate or other methods.
- FPLC fast performance liquid chromatography
- HPLC HPLC
- precipitation of apolipoprotein B containing proteins with dextran sulfate or other methods Any of a number of standard aqueous buffer solutions at physiological pH, such as phosphate, Tris, or the like, can be used.
- the term “subject” generally refers to any vertebrate, including, but not limited to a mammal Examples of mammals including primates, including simians and humans, equines (e.g., horses), canines (e.g., dogs), felines, various domesticated livestock (e.g., ungulates, such as swine, pigs, goats, sheep, and the like), as well as domesticated pets (e.g., cats, hamsters, mice, and guinea pigs). Treatment or diagnosis of humans is of particular interest.
- Cowden syndrome also known as Cowden's disease and multiple hamartoma syndrome
- Cowden syndrome is an autosomal dominant inherited condition characterized by benign overgrowths called hamartomas as well as an increased lifetime risk of breast, thyroid, uterine, and other cancers. It is often underdiagnosed due to variability in disease presentation, but 99% of patients report mucocutaneous symptoms by age 20-29.
- Cowden's syndrome is a multi-system disorder that also includes neurodevelopmental disorders such as macrocephaly.
- Cowden syndrome is a great clinical mimic and can be difficult to recognize because every patient shows variable expression and penetrance. Many individuals in the general population share one or more features of Cowden syndrome but may not have Cowden syndrome and may not even harbor alterations in any predisposition genes. The presentation of Cowden syndrome is strikingly diverse; some patients exhibit characteristic features without meeting diagnostic criteria for CS. Cowden-like syndrome (CLS) is the diagnosis in these patients, few of whom have mutations in PTEN or variants in the succinate dehydrogenase (SDHB) gene.
- CCS Cowden-like syndrome
- the subject has germline PTEN mutations.
- Cowden syndrome is associated with mutations in the phosphatase and tensin homolog (PTEN) gene (UCSC ID, uc001kfb.2; RefSeq, NM_000314) on 10q23.3, a tumor suppressor gene otherwise known as phosphatase and tensin homolog, that results in dysregulation of the mTOR pathway leading to errors in cell proliferation, cell cycling, and apoptosis.
- Germline mutations of the PTEN gene encoding deletions on chromosome 10, cause 25% of autosomal-dominant Cowden syndrome which minimally occur in 1 in 200,000 live births.
- the germline PTEN mutations are pathogenic germline PTEN mutations. Pathogenicity predictions were ascertained by reports from orthogonal testing in a Clinical Laboratory Improvement Amendments of 1988—certified facility, ClinVar database classifications, and/or the ClinGen gene-specific criteria for PTEN variant curation. Mester et al., Hum Mutat., 39(11):1581-1592 (2016).
- the method is used to determine whether the subject has a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer.
- tumor or “cancer” refer to a condition characterized by anomalous rapid proliferation of abnormal cells of a subject.
- the abnormal cells often are referred to as “neoplastic cells,” which are transformed cells that can form a solid tumor.
- tumor refers to an abnormal mass or population of cells (e.g., two or more cells) that result from excessive or abnormal cell division, whether malignant or benign, and pre-cancerous and cancerous cells.
- Malignant tumors are distinguished from benign growths or tumors in that, in addition to uncontrolled cellular proliferation, they can invade surrounding tissues and can metastasize.
- the method of diagnosis includes the step of conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample.
- the genomic DNA comprises the PTEN region, while in further embodiments the DNA comprises the PTEN promoter region.
- “Mutation and deletion analysis” is defined herein as the study or analysis of DNA fragments to determine if the fragments contain variations (i.e., mutations or deletions) in a population.
- Mutations on germline or somatic DNA include mis-sense and nonsense mutations, SNPs (single nucleotide polymorphisms) deletions and insertions.
- the mutation analysis comprises denaturing gradient gel electrophoresis, high-resolution melting curve analysis, and directed Sanger sequencing.
- Other types of mutation analysis include single-strand conformation polymorphism (SSCP) analysis, SSCP/heteroduplex analysis, enzyme mismatch cleavage, allele-specific hybridization, and restriction analysis of the genomic DNA.
- SSCP single-strand conformation polymorphism
- the mutation analysis is specifically interested in detecting deletions, in which case it is referred to as deletion analysis. Methods of conducting deletion analysis are also known to those skilled in the art. In some embodiments, the deletion analysis is conducted using a multiplex ligation-dependent probe amplification assay.
- PCR polymerase chain reaction
- PCR refers to the methods of U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, all of which are hereby incorporated by reference, directed to methods for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification.
- methods for determining a nucleic sequence involving PCR include quantitative RT-PCR, Northern blot, real-time PCR, PCR, allele-specific PCR, pyrosequencing, SNP Chip technology, and restriction fragment length polymorphism (RFLP).
- hybridization with complementary sequences may be used to detect the presence of germline PTEN mutations based on the different characteristics of sequences that have a complete or incomplete sequence match.
- an asymmetric PCR assay can be used in which fluorescence melting reveals two distinct melting temperatures of the probe/target duplex that are specific for the amplified sequence.
- the method comprises single-nucleotide polymorphism genotype quality control, in order to correct for population stratification.
- DNA quality can be evaluated using spectrophotometry.
- Genotype quality control can include the use of principal component analysis to assess population stratification. Quality control commonly includes algorithmic processing of the nucleotide sequence data, such as intensity-based quality control to exclude samples with low quality based on waviness factor.
- the method of diagnosis also includes the step of determining the level of copy number variation in the genomic DNA.
- Copy number variation is a type of structural variation where you have a stretch of DNA, which can be duplicated, or sometimes even triplicated or quadruplicated. Therefore, when you look at that chromosomal region, you will see a variation in the number of copies.
- those copy number variants include genes, maybe several genes, which may mean that an individual has four copies of that gene instead of the usual two, while a different individual has three, and a further individual has five.
- determining copy number variation includes the steps of: a. providing at least two sets of first polynucleotides, wherein each set maps to a different reference sequence in a genome, and, for each set of first polynucleotides; i.
- amplifying the polynucleotides to produce a set of amplified polynucleotides ii. sequencing a subset of the set of amplified polynucleotides, to produce a set of sequencing reads; iii. grouping sequences reads sequenced from amplified polynucleotides into families, each family amplified from the same first polynucleotide in the set; iv. inferring a quantitative measure of families in the set; v. determining copy number variation by comparing the quantitative measure of families in each set.
- the level of copy number variation in the genomic DNA is compared to a control value to determine the relative level of copy number variation.
- the control value can be the level of copy number variation in subjects having Cowden-like syndrome or PTEN germline mutations. Alternately, the control value can be the level of copy number variation in subjects having Cowden-like syndrome or PTEN germline mutations who have been diagnosed with cancer.
- the presence and/or levels of copy number variation can be displayed in a variety of ways.
- the levels can be displayed graphically on a display as numeric values or proportional bars (i.e., a bar graph) or any other display method known to those skilled in the art.
- the graphic display can provide a visual representation of the amount of copy number variation in the biological sample being evaluated.
- a subject can be diagnosed as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.
- FIG. 2 patients with autism spectrum disorder (ASD) or developmental delay (DD) show higher levels of copy number variation.
- ASD autism spectrum disorder
- DD developmental delay
- cancer patients having Cowden-like syndrome or PTEN germline mutations may show a level of copy number variation of about 1%-2%
- patients having a neurodevelopmental disorder such as ASD or DD may show a level of copy number variation of about 3%-15%, 5%-15%, 8%-12%, or about 10%.
- subjects that have neither cancer nor a neurodevelopmental disorder may show a level of copy number variation of from about 2% to about 3%.
- Another aspect of the invention provides a method of treating a subject who has been diagnosed as having or having an increased risk of having a neurodevelopmental disorder.
- the specific type of therapy provided depends on the particular type of neurodevelopmental disorder, though generally the therapy involved physical or behavioral therapy.
- drugs such as glutamate receptor 5 antagonists and GABA B receptor agonists can also be used to treat neurodevelopmental disorders.
- a preferred method for treating ASD is applied heavier analysis (ABA) therapy. Fernandes et al., Codas, 25(3):289-96 (2013).
- CNVs copy number variations
- Cowden-like syndrome Eng C., J Med Genet., 37(11): 828-830 (2000)
- macrocephaly plus neurodevelopmental disorders e.g, ASD, developmental delay [DD], mental retardation
- penile freckling e.g., a known pathogenic germline PTEN mutation
- the inventors reviewed medical records, including pedigrees, clinical genetic testing reports, and clinical notes associated with genetics evaluations, ASD Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) criteria, and/or genetic counseling visits, where applicable. The inventors followed up this cohort prospectively for development of phenotypic features.
- Genomic DNA was extracted from peripheral blood samples using standard protocols. Mutation analysis was standardly performed, with a combination of denaturing gradient gel electrophoresis, high-resolution melting curve analysis (Idaho Technology), and direct Sanger sequencing (ABI 3730xl; Applied Biosystems, Life Technologies). Deletion analysis using the multiplex ligation-dependent probe amplification assay was performed with the multiplex ligation-dependent probe amplification kit (P158; MRC-Holland) according to manufacturer protocol. Ngeow et al., J Clin Oncol., 32(17):1818-1824 (2014). All patients underwent polymerase chain reaction-based Sanger sequencing of the PTEN promoter region.
- DNA quality was evaluated using spectrophotometry (NanoDrop 1000; Thermo Fisher Scientific) and quantity using a double-stranded DNA high-sensitivity assay kit (Qubit; Thermo Fisher Scientific).
- DNA samples were all genotyped on a commercially available genotyping array (Infinium Global Screening Array-24, version 1.0; Illumina) at the Broad Institute Genomic Services, Cambridge, Mass. A total of 642 824 markers were used for quality control.
- SNP single-nucleotide polymorphism
- the inventors focused on autosomal CNVs owing to higher fidelity of CNV calling compared with sex chromosomes. Pinto et al., Nat Biotechnol., 29(6):512-520 (2011). To perform principal component analysis to assess population stratification, autosomal SNPs with low genotyping rates (>0.98) and deviation from Hardy-Weinberg equilibrium (P ⁇ 0.001) were filtered before pruning SNPs for linkage disequilibrium using default parameters in PLINK, version 1.927 (--indep-pairwise 200 100 0.2). Chang et al., Gigascience, 4:7 (2015). The PennCNV algorithm (Wang et al.
- Genome Res., 17(11):1665-1674 (2007)) was used to generate GC DNA nucleotide wave-adjusted log R ratio intensity files and to call CNVs in all samples.
- a custom population B-allele frequency file was generated before CNV calling. Adjacent CNV calls were merged if the number of intervening markers was less than 20% of the total number than when both segments were combined.
- the inventors performed intensity-based quality control to exclude samples with low quality based on waviness factor, log R ratio SD, and B-allele frequency drift. These thresholds were calculated by taking the median plus 3 SD to identify outliers. Huang et al; Neuron., 94(6):1101-1111 (2017).
- CNVs spanning less than 20 markers, CNVs of less than 20 Kb in length, CNVs with SNP density (number of markers/CNV length) of less than 0.0001, and/or CNVs with greater than 50% of total length overlapping artifactual regions in SNP-based CNV calling were excluded. Marshall et al., Nat. Genet. 49(1):27-35 (2017). The final data set consisted of 309 patients of genotype-determined European ancestry with at least 1 CNV call.
- the CNV burden among patients with PHTS and ASD and/or developmental delay (ASD/DD group), those without ASD or developmental delay (no ASD/DD group), and those with cancer was measured. Genome-wide burden was also analyzed for only rare CNVs (excluding CNVs overlapping >80% of regions known to be recurrent in the general population). Duplications and deletions were analyzed in combination as well as separately. Moreover, within each category (duplications and deletions), genic and nongenic CNVs were analyzed in combination as well as separately. For all comparisons, the number of unrelated probands with such genomic events was counted within each phenotype group.
- a CNV was considered as genic if it overlapped more than 80% of a gene (Coppola et al., Epilepsia, 60(4), 689-706 (2019)); otherwise it was annotated as nongenic.
- Cancer-relevant loci included 46 genes associated with Cowden syndrome component cancers, of which 24 are clinically actionable cancer-related genes according to the American College of Medical Genetics and Genomics guidelines. Yehia et al., PLoS Genet., 14(4):e1007352 (2016). Genes associated with ASD were curated from the Simons Foundation Autism Research Initiative Gene module.32 Only syndromic (category S), high-confidence (category 1), and strong candidate (category 2) genes were retained.
- the inventors also interrogated regions associated with genomic disorders, congenital malformations, and neurodevelopmental phenotypes, including 48 loci from DECIPHER (Database of Chromosomal Imbalance and Phenotype Using Ensembl Resources), 298 genes from the Developmental Disorders Genotype-Phenotype Database, and 92 loci of pathogenic CNVs from the UK Biobank. Pathogenicity and likely pathogenicity of previously unreported CNVs were estimated based on size and gene content according to the American College of Medical Genetics and Genomics guidelines. Human Phenotype Ontology terms were used for standard annotation of CNVs with associated phenotypic abnormalities.
- Patients with PHTS were stratified into 3 phenotypically ascertained groups, including the ASD/DD group, no ASD/DD group, and cancer group (a subset of the no ASD/DD group). They did not include a no cancer group owing to the inability to ascertain cancer diagnoses, particularly in pediatric, adolescent, and young adult patients. Importantly, the PTEN mutation spectra were similar across the 3 PHTS phenotype groups ( FIGS. 3A-3C ).
- the analytic sample consisted of 309 patients with PHTS (Table 1) of genetically determined European ancestry (mean [SD] age at consent, 32.0 [21.0] years; 167 female [54.0%] and 142 male [46.0%]).
- Phenotypically ascertained groups consisted of 110 unrelated patients in the ASD/DD phenotype group, 194 unrelated patients in the no ASD/DD phenotype group, and a subset of 121 unrelated patients, including 116 in the no ASD/DD group, with cancer.
- the total number of CNVs in each participant were quantified within the 3 PHTS phenotype groups ( FIG. 1A ).
- c Includes trichilemmoma, acral keratosis, papillomatous papules, and genital lentiginosis (penile freckling in males).
- d Includes breast fibroadenoma, fibrocystic breast disease, breast papilloma, breast hamartoma, atypical ductal hyperplasia, and typical ductal hyperplasia.
- e Includes thyroid nodules, goiter, and Hashimoto thyroiditis. Clinically Relevant CNVs in Patients with PHTS
- the inventors identified 3 of 309 patients with PHTS (1.07%) and pathogenic and/or likely pathogenic CNVs affecting genes associated with PTEN-related cancers or other inherited cancer syndromes according to the American College of Medical Genetics and Genomics guidelines. These included 2 BMPR1A (OMIM 601299) deletions and 1 BRCA1 (OMIM 113705) deletion. The inventors could not ascertain cancer diagnoses because all 3 CNV carriers were children or young adults (aged 3, 6, and 21 years) without a personal history of cancer at the time of consent. The 2 patients with PHTS and BMPR1A deletions upstream of their individual PTEN deletion had juvenile polyposis, as is often observed in chromosome 10q23 microdeletions involving both genes (OMIM 612242). Notably, no pathogenic and/or likely pathogenic CNVs involving known cancer-associated genes were identified among patients in the subset with cancer.
- Pathogenic and/or likely pathogenic CNVs involving genes implicated in the etiology of idiopathic non-syndromic and syndromic ASD/developmental delay and/or neurodevelopmental disorders as well as known pathogenic CNVs associated with ASD, developmental delay, and neurodevelopmental disorders were then investigated.
- the CNV carriers included 10 male and 6 female patients with PHTS (mean [SD] age at consent, 22 [22.1] years).
- the CNVs included genomic loci associated with other genomic syndromes with overlapping clinical features, such as chromosome 8p23.1 duplication syndrome and chromosome 1q21.1 thrombocytopenia-absent radius syndrome.
- the present study evaluated the association of CNVs with clinical outcomes, specifically cancer vs ASD/DD, in individuals with germline pathogenic PTEN mutations.
- the inventors found that patients with PHTS and ASD/DD have an overall increased genome-wide CNV burden per individual and an enrichment of clinically relevant CNVs when compared with the subset of patients with cancer and those without ASD/DD.
- CNVs may act as genomic modifiers of disease risk in phenotypically heterogeneous hereditary disorders such as PHTS.
- pathogenic and likely pathogenic CNVs are associated with ASD/DD risk regardless of the particular coexisting germline PTEN mutation.
- Autism spectrum disorder is believed to be a highly heritable disorder, with complex genetic and biological basis.
- Pathogenic CNVs have been identified in 8% to 21% of individuals with idiopathic ASD, with higher frequencies reported in more severe cases, including causing syndromic ASD.
- Schaefer et al. Genet Med., 15(5):399-407 (2013).
- particular pathogenic CNVs have also been identified in neurotypical control individuals, including unaffected family members, albeit with significantly lower frequencies.
- Heil K M Schaaf C P., Curr Psychiatry Rep., 15(1):334 (2013).
- CYFIP1 encodes cytoplasmic FMR1-interacting protein 1, a protein originally found to interact with fragile X mental retardation protein. Increased CYFIP1 dosage has been shown to cause aberrant neuronal cellular and dendritic morphologic features and to be associated with ASD in humans and murine model organisms. Noroozi et al., Metab Brain Dis., 33(4):1353-1358 (2018).
- CYFIP1 expression was inversely correlated with PTEN expression levels, with concomitant dysregulation of mammalian target of rapamycin (mTOR) signaling, suggesting that such CNVs may represent a second hit for patients with PHTS already harboring deleterious PTEN mutations that upregulate AKT-mTOR signaling.
- mTOR mammalian target of rapamycin
- CYFIP1 deletion As was observed for 1 of the 3 patients with PHTS and CNVs involving CYFIP1 in this study, increased levels of a mutant PTEN protein may result in dominant negative effects (Papa et al., Cell, 157(3):595-610 (2014)), inhibiting wild-type PTEN and hence exacerbating the condition.
- CNVs have also been implicated in the etiology of neuropsychiatric diseases such as epilepsy, schizophrenia, and bipolar disorder. Merikangas et al., Trends Genet., 25(12):536-544 (2009).
- a broad spectrum of neuropsychiatric phenotypes has been observed in patients with PHTS ranging from normal development and intelligence to severely debilitating neurocognitive and motor aberrations, including generalized anxiety, adult-onset movement disorders, obsessive-compulsive disorder, and psychosis. Whether particular CNVs affect the spectrum or severity of such motor and/or neurocognitive disease manifestations in PHTS warrants further scrutiny in larger independent prospective series.
- testable clinically relevant genomic modifiers in PHTS is important for risk stratification and serves as proof of principle for other phenotypically variable disorders.
- Patients with PHTS and ASD/DD have an increased burden of pathogenic and/or likely pathogenic CNVs associated with neurodevelopmental disorders.
- CNV analysis is indicated as a first-tier clinical diagnostic test for patients with unexplained ASD/DD, it is not standard to test for such genomic alterations in the setting of an established diagnosis with a syndromic high-penetrance mendelian gene such as PTEN. Copy number variation analysis on immediate identification of germline PTEN mutation in infants and children may be beneficial.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- This application claims priority to U.S. Provisional Patent Application No. 62/951,518, filed on Dec. 20, 2019, which is hereby incorporated by reference in its entirety.
- This invention was made with government support under Grant Nos. CA118989, CA124570, and NS092090 awarded by the National Institutes of Health. The U.S. Government has certain rights in this invention.
- The triumph of using genetics in precision medicine is the ability to stratify individuals at very high risk of disease and thereby enact specific gene-informed medical management. Topol E J, Cell., 157(1):241-253 (2014). In the case of heritable disease, genetics also allow testing of family members to determine with 100% accuracy whether they are at risk of disease. However, for any single individual carrying a mutation, the risk can be estimated by probabilities but not with certainty. For example, a germline mutation in gene X may give an 80% lifetime risk of disease Y, but for the single patient with that germline mutation, the risk of developing disease Y will be 100% or 0%. Searching for genomic modifiers of heritable disease risk at the individual level in humans has proven challenging. This makes estimation of clinical outcomes difficult, especially for phenotypically variable disorders. As such, why a mutation in one particular gene predisposes to disparate clinical outcomes, including in patients with identical mutations, remains poorly understood.
- PTEN germline mutations include mutations of the phosphatase and tensin homolog (PTEN) gene (UCSC ID, uc001kfb.2; RefSeq, NM_000314), encoding deletions on
chromosome 10. PTEN germline mutations are among the most common causes of autism spectrum disorder (ASD), accounting for approximately 2% to 5% of cases (Butler et al., J Med Genet., 42(4): 318-321 (2005)), yet originally identified in a subset of relatively rare syndromes predisposing to breast, thyroid, and other cancers. Liaw et al., Nat Genet., 16(1):64-67 (1997). The PTEN-related ASD-cancer phenotypic dichotomy and inability to preemptively estimate disease outcomes pose a challenge for more timely and precise clinical management. The concept of PTEN hamartoma tumor syndrome (PHTS) was proposed to encompass any clinical disorder with germline PTEN mutation on molecular genetic testing, regardless of phenotype. Marsh et al., Hum Mol Genet., 8(8):1461-1472 (1999). Based on this broad clinical spectrum and unified genetic etiology, PHTS serves as a useful disease model to identify modifiers of variable heritable disease risk at the individual level. - Copy number variation (CNV), a common type of structural variation in the human genome, is considered an important contributor to non-syndromic idiopathic ASD and sporadic cancer. Jeste S S, Geschwind D H., Nat Rev Neurol., 10(2):74-81 (2014); Huang et al; Cell, 173(2):355-370.e14 (2018). Copy number variations have also been associated with complex disorders, particularly those involving developmental delay, intellectual disabilities, and/or congenital anomalies. Miller et al., Am J Hum Genet., 86(5):749-764 (2010). However, it was not known whether specific CNV associations in patients carrying germline PTEN mutations are associated with development of specific clinical phenotypes at an individual level.
- The present invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations. The method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value. In some embodiments, a copy number variation level that is higher than the control value indicates a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer.
- In some embodiments, the neurodevelopmental disorder is autism spectrum disorder. In further embodiments, the genomic DNA comprises the PTEN promoter region. In yet further embodiments, the deletion analysis is conducted using a multiplex ligation-dependent probe amplification assay.
- In some embodiments, the mutation analysis comprises denaturing gradient gel electrophoresis, high-resolution melting curve analysis, and directed Sanger sequencing. In additional embodiments, the step of determining the level of copy number variation comprises single-nucleotide polymorphism genotype quality control.
- In some embodiments, the subject has Cowden-like syndrome. In further embodiments, the subject has PTEN germline mutations. In yet further embodiments, the germline PTEN mutations are pathogenic germline PTEN mutations.
- The inventors conducted a prospective cohort study that examined genome-wide microarrays performed on blood-derived DNA to detect germline CNVs from participants, including patients with PTEN hamartoma tumor syndrome (PHTS), molecularly defined as carrying germline pathogenic PTEN mutations. The prevalence of pathogenic and/or likely pathogenic CNVs in patients with PHTS and association with ASD/developmental delay and/or cancer, ascertained through medical records and pathology reports.
- The study included 481 patients with PHTS (mean [SD] age, 33.2 [21.6] years; of which 268 were female [55.7%]). The analytic series consisted of 309 patients with PHTS and genetically determined European ancestry. Patients were divided into 3 phenotypic groups, excluding family members within each group. These include 110 patients with ASD/developmental delay, 194 without ASD/developmental delay, and 121 with cancer (of whom 116 were in the no ASD/developmental delay group).
- Genome-wide evaluation of autosomal CNVs indicated an increased CNV burden, particularly duplications in genic regions, in patients with ASD/developmental delay compared with those without ASD/developmental delay (odds ratio [OR], 1.9; 95% CI, 1.1-3.4; P=0.03) and those with cancer (OR, 2.5; 95% CI, 1.3-4.6; P=0.003). Eleven of the 110 patients (10.0%) with ASD/developmental delay carried pathogenic and/or likely pathogenic CNVs associated with neurodevelopmental disorders, compared with 5 of 194 (2.6%) without ASD/developmental delay (OR, 4.2; 95% CI, 1.4-13.7; P=0.008) and 2 of 121 (1.7%) with cancer (OR, 6.6; 95% CI, 1.6-44.5; P=0.007). Evidence of an association between pathogenic and/or likely pathogenic CNVs and PHTS with ASD/developmental delay was further supported in a validation series of 69 patients with PHTS of genetically determined non-European ancestry. These findings indicate that copy number variations are associated with the ASD/developmental delay clinical phenotype in PHTS, providing proof of principle for similarly heterogeneous disorders lacking outcome-specific associations.
- The present invention may be more readily understood by reference to the following figures, wherein:
-
FIGS. 1A and 1B provide graphs showing (A) Genome-wide CNV burden representing the total number of CNVs in each patient within the 3 PHTS phenotype groups. The line in the middle of each box is plotted at the median. Each box extends from the 25th to 75th percentiles (interquartile range [IQR]). Whiskers and outliers (circles) are plotted according to the Tukey method. The upper whiskers extend to the largest value no further than 1.5 times the IQR. The lower whiskers extend to the smallest value no further than 1.5 times the IQR; (B) Stratified analyses showing CNV burden (duplications and deletions) in genic and nongenic genomic regions, accounted for by the number of unrelated patients carrying such CNVs within each clinical phenotype group. The size of each box is proportional to the respective odds ratio (OR) depicted in the adjacent table. ASD indicates autism spectrum disorder; DD, developmental delay. -
FIG. 2 provides a graph showing pathogenic and/or likely pathogenic CNVs associated with neurodevelopmental disorders were found in 11 of 110 patients in the ASD/DD group (10.0%), 5 of 194 patients in the no ASD/DD group (2.6%), and 2 of 121 patients in the subgroup with cancer (1.7%). The size of each box is proportional to the respective odds ratio (OR) depicted in the adjacent table. -
FIGS. 3A-3C provides graphs showing PTEN mutation spectra across the PHTS Clinical Phenotype Groups. PTEN mutations are depicted in the lollipop plots overlying the PTEN protein structures. The frequency of each mutation correlates with the heights of the vertical lines representing each lollipop. A, PTEN mutations identified in PHTS individuals with autism spectrum disorder/developmental delay (ASD/DD). Three whole PTEN gene deletions, oneexon 1 deletion, and oneexon 1 duplication are not depicted. B, PTEN mutations identified in PHTS individuals without ASD/DD, including the subset with cancer. Two whole PTEN gene deletions, threeexon 1 deletions, two exon 1-2 deletions, one exon 6 duplication, one exon 2-9 duplication, and 21 promoter mutations are not depicted. C, PTEN mutations identified in PHTS individuals with cancer. One whole PTEN gene deletion, oneexon 1 deletion, one exon 1-2 deletions, one exon 6 duplication, and 20 promoter mutations are not depicted. The cBioPortal MutationMapper tool was used to depict the identified PTEN germline mutations. Family members were excluded from each PHTS phenotype group. The ‘other’ category includes the PTEN p.M11 start loss mutation. - The present invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations. The method includes the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value.
- As used herein, the term “diagnosis” can encompass determining the likelihood that a subject will develop a disease, or the existence or nature of disease in a subject. The term diagnosis, as used herein also encompasses determining the severity and probable outcome of disease or episode of disease or prospect of recovery, which is generally referred to as prognosis). “Diagnosis” can also encompass diagnosis in the context of rational therapy, in which the diagnosis guides therapy, including initial selection of therapy, modification of therapy (e.g., adjustment of dose or dosage regimen), and the like.
- As used herein, the terms “treatment,” “treating,” and the like, refer to obtaining a desired pharmacologic or physiologic effect. The effect may be therapeutic in terms of a partial or complete cure for a disease or an adverse effect attributable to the disease. “Treatment,” as used herein, covers any treatment of a disease in a mammal, particularly in a human, and can include inhibiting the disease or condition, i.e., arresting its development; and relieving the disease, i.e., causing regression of the disease.
- Prevention or prophylaxis, as used herein, refers to preventing the disease or a symptom of a disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it (e.g., including diseases that may be associated with or caused by a primary disease). Prevention may include completely or partially preventing a disease or symptom.
- The term “polynucleotide” or “nucleic acid molecule” refers to a polymeric form of nucleotides of at least 10 bases in length. The term includes DNA molecules (e.g., cDNA or genomic or synthetic DNA) and RNA molecules (e.g., mRNA or synthetic RNA), as well as analogs of DNA or RNA containing non-natural nucleotide analogs, non-native inter-nucleoside bonds, or both. The nucleic acid can be in any topological conformation. For instance, the nucleic acid can be single-stranded, double-stranded, triple-stranded, quadruplexed, partially double-stranded, branched, hair-pinned, circular, or in a padlocked conformation.
- The term “gene” as used herein refers to a nucleotide sequence that can direct synthesis of an enzyme or other polypeptide molecule (e.g., can comprise coding sequences, for example, a contiguous open reading frame (ORF) which encodes a polypeptide) or can itself be functional in the organism. A gene in an organism can be clustered within an operon, as defined herein, wherein the operon is separated from other genes and/or operons by intergenic DNA. Individual genes contained within an operon can overlap without intergenic DNA between the individual genes.
- The term “genotype” refers to the alleles present in DNA from a subject or patient, where an allele can be defined by the particular nucleotide(s) present in a nucleic acid sequence at a particular site(s). Often a genotype is the nucleotide(s) present at a single polymorphic site known to vary in the human population.
- A “germline mutation,” as used herein, refers to a heritable change in the DNA that occurred in a germ cell (a cell destined to become an egg or in the sperm) or the zygote (the conceptus) at the single-cell stage. When transmitted to a child, a germline mutation is incorporated in every cell of their body.
- “Copy number variation,” as used herein, revers to a number of genes that is different from the norm (which is typically two copies). Variation in the copy number is generally caused by deletion or duplication of genes.
- As used herein, the term “polymorphism” refers to a difference in the nucleotide sequence of a given region as compared to a nucleotide sequence in a homologous region of another individual, in particular, a difference in the nucleotide sequence of a given region that differs between individuals of the same species. Polymorphisms include single nucleotide differences, differences in sequence of more than one nucleotide, insertions, inversions and deletions. The term refers to the occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%. A polymorphic locus can be as small as one base pair.
- Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
- As used herein, the term “about,” when referring to a value or to an amount of mass, weight, time, volume, concentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments ±10%, in some embodiments ±5%, in some embodiments ±1%, in some embodiments ±0.5%, and in some embodiments ±0.1% from the specified amount, as such variations are appropriate to perform the disclosed method.
- As used herein and in the appended claims, the singular forms “a”, “and”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a sample” also includes a plurality of such samples.
- Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
- One aspect of the invention provides a method of providing a diagnosis for a subject having Cowden-like syndrome or PTEN germline mutations, the method comprising the steps of: (a) obtaining a biological sample from a subject; (b) conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample; (c) determining the level of copy number variation in the genomic DNA; (d) comparing the level of copy number variation in the genomic DNA to a control value for copy number variation; and (e) diagnosing the subject as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value. In some embodiments, a copy number variation level that is higher than the control value indicates a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer.
- The present invention provides methods for diagnosing subjects having an increased risk of developing a neurodevelopmental disorder. Neurodevelopmental disorders are disabilities associated primarily with the functioning of the neurological system and brain. Examples of neurodevelopmental disorders in children include attention-deficit/hyperactivity disorder (ADHD), autism, learning disabilities, intellectual disability (also known as mental retardation), conduct disorders, cerebral palsy, and impairments in vision and hearing. Learning disability (or learning disorder) is a general term for a neurological disorder that affects the way in which a child's brain can receive, process, retain, and respond to information. Children with neurodevelopmental disorders can experience difficulties with language and speech, motor skills, behavior, memory, learning, or other neurological functions.
- In some embodiments, the neurodevelopmental disorder is autism spectrum disorder. Autism spectrum disorders (ASDs) are a group of developmental disabilities defined by significant social, communication, and behavioral impairments. The term “spectrum disorders” refers to the fact that although people with ASDs share some common symptoms, ASDs affect different people in different ways, with some experiencing very mild symptoms and others experiencing severe symptoms. ASDs encompass autistic disorder and the generally less severe forms, Asperger's syndrome and pervasive developmental disorder-not otherwise specified (PDD-NOS). Children with ASDs may lack interest in other people, have trouble showing or talking about feelings, and avoid or resist physical contact. A range of communication problems are seen in children with ASDs: some speak very well, while many children with an ASD do not speak at all. Another hallmark characteristic of ASDs is the demonstration of restrictive or repetitive interests or behaviors, such as lining up toys, flapping hands, rocking his or her body, or spinning in circles. Examples of ASDs are autistic disorder, Asperger's disorder, and pervasive developmental disorder. McPartland, J., and Volkmar, F., Handb Clin Neurol, 106:407-18 (2012).
- The method of diagnosis includes the step of obtaining a biological sample from a subject. A “biological sample,” as used herein, is meant to include any biological sample from a subject that is suitable for detection and analysis of the copy number variation in the genomic DNA of the subject. Suitable biological samples include but are not limited to bodily fluids such as blood-related samples (e.g., whole blood, serum, plasma, and other blood-derived samples), urine, sputem, cerebral spinal fluid, bronchoalveolar lavage, and the like. Another example of a biological sample is a tissue sample. In some embodiments, the biological sample is a cancer cell or tissue including cancer cells. The copy number variation in the genomic DNA of the subject can be assessed either quantitatively or qualitatively, and detection can be conducted either in vitro or ex vivo.
- The methods involve providing or obtaining a biological sample from the subject, which can be obtained by any known means including needle stick, needle biopsy, swab, and the like. In an exemplary method, the biological sample is a blood sample, which may be obtained for example by venipuncture.
- A biological sample may be fresh or stored. Biological samples may be or have been stored or banked under suitable tissue storage conditions. The biological sample may be a tissue sample expressly obtained for the assays of this invention or a tissue sample obtained for another purpose which can be subsampled for the assays of this invention. Preferably, biological samples are either chilled or frozen shortly after collection if they are being stored to prevent deterioration of the sample.
- The sample may be pretreated as necessary by dilution in an appropriate buffer solution, heparinized, concentrated if desired, or fractionated by any number of methods including but not limited to ultracentrifugation, fractionation by fast performance liquid chromatography (FPLC) or HPLC, or precipitation of apolipoprotein B containing proteins with dextran sulfate or other methods. Any of a number of standard aqueous buffer solutions at physiological pH, such as phosphate, Tris, or the like, can be used.
- The terms “individual,” “subject,” and “patient” are used interchangeably herein irrespective of whether the subject has or is currently undergoing any form of treatment. As used herein, the term “subject” generally refers to any vertebrate, including, but not limited to a mammal Examples of mammals including primates, including simians and humans, equines (e.g., horses), canines (e.g., dogs), felines, various domesticated livestock (e.g., ungulates, such as swine, pigs, goats, sheep, and the like), as well as domesticated pets (e.g., cats, hamsters, mice, and guinea pigs). Treatment or diagnosis of humans is of particular interest.
- In some embodiments, the subject has Cowden syndrome or Cowden-like syndrome. Cowden syndrome (also known as Cowden's disease and multiple hamartoma syndrome) is an autosomal dominant inherited condition characterized by benign overgrowths called hamartomas as well as an increased lifetime risk of breast, thyroid, uterine, and other cancers. It is often underdiagnosed due to variability in disease presentation, but 99% of patients report mucocutaneous symptoms by age 20-29. Cowden's syndrome is a multi-system disorder that also includes neurodevelopmental disorders such as macrocephaly.
- Cowden syndrome is a great clinical mimic and can be difficult to recognize because every patient shows variable expression and penetrance. Many individuals in the general population share one or more features of Cowden syndrome but may not have Cowden syndrome and may not even harbor alterations in any predisposition genes. The presentation of Cowden syndrome is strikingly diverse; some patients exhibit characteristic features without meeting diagnostic criteria for CS. Cowden-like syndrome (CLS) is the diagnosis in these patients, few of whom have mutations in PTEN or variants in the succinate dehydrogenase (SDHB) gene.
- Only 5% of the heterogeneous group having Cowden-like syndrome and who have some features of Cowden syndrome but do not meet diagnostic criteria, have germline PTEN mutations. In the absence of germline PTEN mutations, approximately 10% of individuals with Cowden syndrome or Cowden-like syndrome harbor germline succinate dehydrogenase variants SDHB and SDHD. Overall, germline PTEN mutations and deletions and SDHx variants account for 35% of Cowden syndrome and 6% to 11% of individuals with Cowden-like syndrome phenotypic features.
- In some embodiments, the subject has germline PTEN mutations. Cowden syndrome is associated with mutations in the phosphatase and tensin homolog (PTEN) gene (UCSC ID, uc001kfb.2; RefSeq, NM_000314) on 10q23.3, a tumor suppressor gene otherwise known as phosphatase and tensin homolog, that results in dysregulation of the mTOR pathway leading to errors in cell proliferation, cell cycling, and apoptosis. Germline mutations of the PTEN gene, encoding deletions on
chromosome 10, cause 25% of autosomal-dominant Cowden syndrome which minimally occur in 1 in 200,000 live births. These mutations result in a syndrome characterized by macrocephaly and typical mucocutaneous features (trichilemmomas, papillomatous papules) and hamartomas, with increased risk of various malignancies, approximately 28% lifetime risk for thyroid cancer, and as much as 50% lifetime risk for female breast cancer over the general population. - In some embodiments, the germline PTEN mutations are pathogenic germline PTEN mutations. Pathogenicity predictions were ascertained by reports from orthogonal testing in a Clinical Laboratory Improvement Amendments of 1988—certified facility, ClinVar database classifications, and/or the ClinGen gene-specific criteria for PTEN variant curation. Mester et al., Hum Mutat., 39(11):1581-1592 (2018).
- In some embodiments, the method is used to determine whether the subject has a higher risk of developing a neurodevelopmental disorder than the risk of developing cancer. As used herein, the terms “tumor” or “cancer” refer to a condition characterized by anomalous rapid proliferation of abnormal cells of a subject. The abnormal cells often are referred to as “neoplastic cells,” which are transformed cells that can form a solid tumor. The term “tumor” refers to an abnormal mass or population of cells (e.g., two or more cells) that result from excessive or abnormal cell division, whether malignant or benign, and pre-cancerous and cancerous cells. Malignant tumors are distinguished from benign growths or tumors in that, in addition to uncontrolled cellular proliferation, they can invade surrounding tissues and can metastasize.
- The method of diagnosis includes the step of conducting a germline PTEN mutation and deletion analysis of genomic DNA from the biological sample. In some embodiments the genomic DNA comprises the PTEN region, while in further embodiments the DNA comprises the PTEN promoter region. “Mutation and deletion analysis” is defined herein as the study or analysis of DNA fragments to determine if the fragments contain variations (i.e., mutations or deletions) in a population.
- Methods of carrying out mutation analysis of DNA are known by those skilled in the art. Mutations on germline or somatic DNA include mis-sense and nonsense mutations, SNPs (single nucleotide polymorphisms) deletions and insertions. In some embodiments, the mutation analysis comprises denaturing gradient gel electrophoresis, high-resolution melting curve analysis, and directed Sanger sequencing. Other types of mutation analysis include single-strand conformation polymorphism (SSCP) analysis, SSCP/heteroduplex analysis, enzyme mismatch cleavage, allele-specific hybridization, and restriction analysis of the genomic DNA.
- In some embodiments, the mutation analysis is specifically interested in detecting deletions, in which case it is referred to as deletion analysis. Methods of conducting deletion analysis are also known to those skilled in the art. In some embodiments, the deletion analysis is conducted using a multiplex ligation-dependent probe amplification assay.
- Many methods of mutation analysis involve PCR. As used herein, the term “polymerase chain reaction” (PCR) refers to the methods of U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,965,188, all of which are hereby incorporated by reference, directed to methods for increasing the concentration of a segment of a target sequence in a mixture of genomic DNA without cloning or purification. Examples of methods for determining a nucleic sequence involving PCR include quantitative RT-PCR, Northern blot, real-time PCR, PCR, allele-specific PCR, pyrosequencing, SNP Chip technology, and restriction fragment length polymorphism (RFLP).
- In some embodiments, hybridization with complementary sequences may be used to detect the presence of germline PTEN mutations based on the different characteristics of sequences that have a complete or incomplete sequence match. For example, an asymmetric PCR assay can be used in which fluorescence melting reveals two distinct melting temperatures of the probe/target duplex that are specific for the amplified sequence.
- In some embodiments, the method comprises single-nucleotide polymorphism genotype quality control, in order to correct for population stratification. For example, in some embodiments, DNA quality can be evaluated using spectrophotometry. Genotype quality control can include the use of principal component analysis to assess population stratification. Quality control commonly includes algorithmic processing of the nucleotide sequence data, such as intensity-based quality control to exclude samples with low quality based on waviness factor.
- The method of diagnosis also includes the step of determining the level of copy number variation in the genomic DNA. Copy number variation is a type of structural variation where you have a stretch of DNA, which can be duplicated, or sometimes even triplicated or quadruplicated. Therefore, when you look at that chromosomal region, you will see a variation in the number of copies. Sometimes those copy number variants include genes, maybe several genes, which may mean that an individual has four copies of that gene instead of the usual two, while a different individual has three, and a further individual has five.
- Methods of determining copy number variation are known to those skilled in the art. See, for example, U.S. patent application Ser. No. 16/913,965; Hastings et al., Nat Rev Genet; 10(8):551-64 (2009); and Shishido et al., Psychiatry Clin Neurosci, 68(2):85-95 (2014), the disclosures of which are incorporated by reference herein. For example, in some embodiments, determining copy number variation includes the steps of: a. providing at least two sets of first polynucleotides, wherein each set maps to a different reference sequence in a genome, and, for each set of first polynucleotides; i. amplifying the polynucleotides to produce a set of amplified polynucleotides; ii. sequencing a subset of the set of amplified polynucleotides, to produce a set of sequencing reads; iii. grouping sequences reads sequenced from amplified polynucleotides into families, each family amplified from the same first polynucleotide in the set; iv. inferring a quantitative measure of families in the set; v. determining copy number variation by comparing the quantitative measure of families in each set.
- After determining the level of copy number variation in the genomic DNA, the level of copy number variation in the genomic DNA is compared to a control value to determine the relative level of copy number variation. The control value can be the level of copy number variation in subjects having Cowden-like syndrome or PTEN germline mutations. Alternately, the control value can be the level of copy number variation in subjects having Cowden-like syndrome or PTEN germline mutations who have been diagnosed with cancer.
- Once the presence and/or levels of copy number variation have been determined, they can be displayed in a variety of ways. For example, the levels can be displayed graphically on a display as numeric values or proportional bars (i.e., a bar graph) or any other display method known to those skilled in the art. The graphic display can provide a visual representation of the amount of copy number variation in the biological sample being evaluated.
- A subject can be diagnosed as having an increased risk of developing a neurodevelopmental disorder if the copy number variation level is higher than the control value. As shown in
FIG. 2 , patients with autism spectrum disorder (ASD) or developmental delay (DD) show higher levels of copy number variation. For example, in some embodiments, cancer patients having Cowden-like syndrome or PTEN germline mutations may show a level of copy number variation of about 1%-2%, while patients having a neurodevelopmental disorder such as ASD or DD may show a level of copy number variation of about 3%-15%, 5%-15%, 8%-12%, or about 10%. Note that subjects that have neither cancer nor a neurodevelopmental disorder may show a level of copy number variation of from about 2% to about 3%. - Another aspect of the invention provides a method of treating a subject who has been diagnosed as having or having an increased risk of having a neurodevelopmental disorder. The specific type of therapy provided depends on the particular type of neurodevelopmental disorder, though generally the therapy involved physical or behavioral therapy. For example, see Lucas et al., BMC Pediatr, 29; 16(1):193 (2016), which describes interventions to improve gross motor performance in children with neurodevelopmental disorders. However, drugs such as
glutamate receptor 5 antagonists and GABAB receptor agonists can also be used to treat neurodevelopmental disorders. Berry-Kravis et al., Nat Rev Drug Discov, 17(4):280-299 (2018). A preferred method for treating ASD is applied heavier analysis (ABA) therapy. Fernandes et al., Codas, 25(3):289-96 (2013). - An example has been included to more clearly describe a particular embodiment of the invention. However, there are a wide variety of other embodiments within the scope of the present invention, which should not be limited to the particular example provided herein.
- PTEN is among the most common autism spectrum disorder (ASD)-predisposition genes. Germline PTEN mutation carriers can develop malignant neoplasms and/or neurodevelopmental disorders such as ASD and developmental delay. Why a single gene contributes to disparate clinical outcomes, even in patients with identical PTEN mutations, was unclear. The objective of this work was therefore to investigate the association of copy number variations (CNVs), altered numbers of copies of DNA sequences within the genome, with specific phenotypes in patients with germline PTEN mutations.
- A total of 6782 patients were prospectively accrued from Sep. 1, 2005, through Jan. 3, 2018, and provided informed written consent to participate. This prospective cohort study was approved by the Cleveland Clinic institutional review board. This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies. Inclusion criteria for enrollment included meeting at least the relaxed International Cowden Consortium operational diagnostic criteria, meaning full diagnostic criteria minus 1 feature, termed Cowden-like syndrome (Eng C., J Med Genet., 37(11): 828-830 (2000)); having macrocephaly plus neurodevelopmental disorders (e.g, ASD, developmental delay [DD], mental retardation) and/or penile freckling; or the presence of a known pathogenic germline PTEN mutation (patients referred to the PTEN Multidisciplinary Clinic at the Cleveland Clinic). These patients were broadly recruited from community and academic medical centers throughout North America, South America, Europe, Australia, and Asia, as noted by Tan et al. Tan et al., Clin Cancer Res. 2012; 18(2):400-407 (2012). After informed consent was obtained, checklists to document the presence or absence of specific features were completed by specialist genetic counselors or physicians concurrently with withdrawal of blood specimen (team led by C.E., medical director, PTEN/Cowden Multidisciplinary Clinic, Center for Personalized Genetic Healthcare, Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio). Specialist genetics staff reviewed all checklists and corresponded with the enrolling center if necessary to obtain further primary documentation of medical records and, for cancer, pathology reports, for phenotype confirmation with patient consent. Tan et al., Am J Hum Genet. 2011; 88(1):42-56 (2011). For each consenting patient, the inventors reviewed medical records, including pedigrees, clinical genetic testing reports, and clinical notes associated with genetics evaluations, ASD Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition, Text Revision) criteria, and/or genetic counseling visits, where applicable. The inventors followed up this cohort prospectively for development of phenotypic features.
- All eligible patients underwent germline PTEN mutation and deletion analysis. Genomic DNA was extracted from peripheral blood samples using standard protocols. Mutation analysis was standardly performed, with a combination of denaturing gradient gel electrophoresis, high-resolution melting curve analysis (Idaho Technology), and direct Sanger sequencing (ABI 3730xl; Applied Biosystems, Life Technologies). Deletion analysis using the multiplex ligation-dependent probe amplification assay was performed with the multiplex ligation-dependent probe amplification kit (P158; MRC-Holland) according to manufacturer protocol. Ngeow et al., J Clin Oncol., 32(17):1818-1824 (2014). All patients underwent polymerase chain reaction-based Sanger sequencing of the PTEN promoter region. Only cases with pathogenic or likely pathogenic germline PTEN mutations were included in the analytic sample. To be conservative, individuals with PTEN promoter variants were considered mutation positive only if the underlying variants had been previously associated with PHTS or known to affect PTEN function. Teresi et al., Am J Hum Genet., 81(4):756-767 (2007); Wang et al., Oncogene, 30(42):4327-4338 (2011). Pathogenicity predictions were ascertained by reports from orthogonal testing in a Clinical Laboratory Improvement Amendments of 1988—certified facility, ClinVar database classifications, and/or the ClinGen gene-specific criteria for PTEN variant curation. Mester et al., Hum Mutat., 39(11):1581-1592 (2018). The resultant data set represents the largest deeply phenotyped worldwide series of patients with PHTS from the International Cowden Consortium.
- DNA quality (A260/A280) was evaluated using spectrophotometry (NanoDrop 1000; Thermo Fisher Scientific) and quantity using a double-stranded DNA high-sensitivity assay kit (Qubit; Thermo Fisher Scientific). DNA samples were all genotyped on a commercially available genotyping array (Infinium Global Screening Array-24, version 1.0; Illumina) at the Broad Institute Genomic Services, Cambridge, Mass. A total of 642 824 markers were used for quality control. To correct for population stratification, single-nucleotide polymorphism (SNP) genotype quality control was performed. Samples with a call rate of less than 0.91 or with discordant sex were excluded. The inventors focused on autosomal CNVs owing to higher fidelity of CNV calling compared with sex chromosomes. Pinto et al., Nat Biotechnol., 29(6):512-520 (2011). To perform principal component analysis to assess population stratification, autosomal SNPs with low genotyping rates (>0.98) and deviation from Hardy-Weinberg equilibrium (P<0.001) were filtered before pruning SNPs for linkage disequilibrium using default parameters in PLINK, version 1.927 (--indep-pairwise 200 100 0.2). Chang et al., Gigascience, 4:7 (2015). The PennCNV algorithm (Wang et al. Genome Res., 17(11):1665-1674 (2007)) was used to generate GC DNA nucleotide wave-adjusted log R ratio intensity files and to call CNVs in all samples. A custom population B-allele frequency file was generated before CNV calling. Adjacent CNV calls were merged if the number of intervening markers was less than 20% of the total number than when both segments were combined. Next, the inventors performed intensity-based quality control to exclude samples with low quality based on waviness factor, log R ratio SD, and B-allele frequency drift. These thresholds were calculated by taking the
median plus 3 SD to identify outliers. Huang et al; Neuron., 94(6):1101-1111 (2017). After intensity-based quality control, all samples had a log R ratio SD of less than 0.25, an absolute waviness factor of less than 0.04, and a B-allele frequency drift of less than 0.007. Samples with an excessively high CNV load (>100) as determined empirically by visual inspection of CNV distribution across a combined set of samples were excluded. None of the PHTS samples had a CNV load above this threshold (with a maximum of 16 CNVs detected in 1 patient). Finally, CNVs spanning less than 20 markers, CNVs of less than 20 Kb in length, CNVs with SNP density (number of markers/CNV length) of less than 0.0001, and/or CNVs with greater than 50% of total length overlapping artifactual regions in SNP-based CNV calling were excluded. Marshall et al., Nat. Genet. 49(1):27-35 (2017). The final data set consisted of 309 patients of genotype-determined European ancestry with at least 1 CNV call. - The CNV burden among patients with PHTS and ASD and/or developmental delay (ASD/DD group), those without ASD or developmental delay (no ASD/DD group), and those with cancer was measured. Genome-wide burden was also analyzed for only rare CNVs (excluding CNVs overlapping >80% of regions known to be recurrent in the general population). Duplications and deletions were analyzed in combination as well as separately. Moreover, within each category (duplications and deletions), genic and nongenic CNVs were analyzed in combination as well as separately. For all comparisons, the number of unrelated probands with such genomic events was counted within each phenotype group.
- A CNV was considered as genic if it overlapped more than 80% of a gene (Coppola et al., Epilepsia, 60(4), 689-706 (2019)); otherwise it was annotated as nongenic. Cancer-relevant loci included 46 genes associated with Cowden syndrome component cancers, of which 24 are clinically actionable cancer-related genes according to the American College of Medical Genetics and Genomics guidelines. Yehia et al., PLoS Genet., 14(4):e1007352 (2018). Genes associated with ASD were curated from the Simons Foundation Autism Research Initiative Gene module.32 Only syndromic (category S), high-confidence (category 1), and strong candidate (category 2) genes were retained. The inventors also interrogated regions associated with genomic disorders, congenital malformations, and neurodevelopmental phenotypes, including 48 loci from DECIPHER (Database of Chromosomal Imbalance and Phenotype Using Ensembl Resources), 298 genes from the Developmental Disorders Genotype-Phenotype Database, and 92 loci of pathogenic CNVs from the UK Biobank. Pathogenicity and likely pathogenicity of previously unreported CNVs were estimated based on size and gene content according to the American College of Medical Genetics and Genomics guidelines. Human Phenotype Ontology terms were used for standard annotation of CNVs with associated phenotypic abnormalities.
- Data were analyzed from Nov. 14, 2018, to Aug. 1, 2019. Patient demographic characteristics were reported by age, sex, and clinical phenotypes. OpenEpi software was used to calculate odds ratios (ORs) for burden and enrichment analyses. For analyses among different patient phenotype groups, 2×2 tables were used to calculate ORs. The 95% CIs and corresponding P values were calculated using the mid-P exact test. The nonparametric Mann-Whitney test was used to analyze CNV burden per individual among the different patient phenotype groups. All P values were 2-sided and considered to be significant at P<0.05. We used Prism 8, version 8.1.1 (GraphPad) to generate box-and-whisker and forest plots.
- At baseline, the inventors prospectively accrued 481 patients with PHTS (mean [SD] age at consent, 33.2 [21.6] years; 268 female [55.7%] and 213 male [44.3%]). The Cleveland Clinic score, a quantitative surrogate of age-related PHTS disease burden, ranged from 0 to 69 (mean [SD], 20 [13]), corroborating the broad phenotypic spectrum, including participants with unexpectedly mild disease manifestations (e.g., absence of early-onset component cancers and neurotypical development) despite their underlying pathogenic germline PTEN mutations. Patients with PHTS were stratified into 3 phenotypically ascertained groups, including the ASD/DD group, no ASD/DD group, and cancer group (a subset of the no ASD/DD group). They did not include a no cancer group owing to the inability to ascertain cancer diagnoses, particularly in pediatric, adolescent, and young adult patients. Importantly, the PTEN mutation spectra were similar across the 3 PHTS phenotype groups (
FIGS. 3A-3C ). - Genome-Wide CNV Burden in Patients with PHTS
- The analytic sample consisted of 309 patients with PHTS (Table 1) of genetically determined European ancestry (mean [SD] age at consent, 32.0 [21.0] years; 167 female [54.0%] and 142 male [46.0%]). Phenotypically ascertained groups consisted of 110 unrelated patients in the ASD/DD phenotype group, 194 unrelated patients in the no ASD/DD phenotype group, and a subset of 121 unrelated patients, including 116 in the no ASD/DD group, with cancer. To determine the genomewide CNV burden, the total number of CNVs in each participant were quantified within the 3 PHTS phenotype groups (
FIG. 1A ). Patients in the ASD/DD group had an overall increased CNV burden per individual (median, 3.5; range, 0-15) compared with those in the no ASD/DD group (median, 3.0; range, 0-13; Mann-Whitney 2-sided test comparing ranks, P=0.04) and the subset with cancer (median, 2.0; range, 0-12; Mann-Whitney 2-sided test, P=0.002). Similarly, patients in the ASD/DD group had an overall increased burden of rare CNVs per individual (median, 3.0; range, 0-14) compared with those in the no ASD/DD group (median, 2.0; range, 0-12; Mann-Whitney 2-sided test comparing ranks, P=0.01) and the subset with cancer (median, 2.0; range, 0-10; Mann-Whitney 2-sided test, P<0.001). No difference was observed in CNV burden among patients in the no ASD/DD group (median, 3.0; range, 0-13) compared with the subset with cancer (median, 2.0; range, 0-12; Mann-Whitney 2-sided test, P=0.15). Similarly, no difference was observed in rare CNV burden among patients in the no ASD/DD group (median, 2.0; range, 0-12) compared with the subset with cancer (median, 2.0; range, 0-10; Mann-Whitney 2-sided test, P=0.19). Stratified analyses according to CNV type and genomic locus revealed that patients in the ASD/DD group had a significant enrichment of duplications in genic regions (FIG. 1B ), compared with patients in the no ASD/DD group (OR, 1.9; 95% CI, 1.1-3.4; P=0.03) and the subset with cancer (OR, 2.5; 95% CI, 1.3-4.6; P=0.003). -
TABLE 1 Clinical Characteristics of the Analytic Series of 309 Patients With PHTS and European Ancestry Clinical Phenotypic Characteristics Data Sex, No. (%) Female 167 (54.0) Male 142 (46.0) Age at consent, mean (SD) [range], y 32 (21) [1-85] No. of germline PTEN mutations Promoter 8 Missense 99 Nonsense 86 Splice site 28 Frameshift truncating 63 Insetions and deletions 25 Neurodevelopment features, No. (%) 110 (35.6) Autism spectrum disorder 45 (14.6) Global development delay 56 (18.1) Variable delay 25 (8.1) Mental retardation 9 (2.9) Learning disabilities 9 (2.9) Cancer, No. (%)a 130 (42.1) PHTS component malignant neoplasms, No. (%) Breast cancer 58 (18.8) Thyroid cancer 36 (11.7) Renal cell cancer 25 (8.1) Endometrial cancer 27 (8.7) Colon cancer 10 (3.2) Melanoma 10 (3.2) Nonmalignant features, No. (%)b 78 (25.2) Macrocephaly 70 (22.7) Dermatologic features' 42 (13.6) Arteriovenous malformations 10 (3.2) Hemangiomas 13 (4.2) Polyposis 38 (12.3) Benign breast featuresd 21 (6.8) Benign thyroid featurese 49 (15.9) Lhermitte-Duclos disease 9 (2.9) Abbreviation: PHTS, PTEN hamartoma tumor syndrome aIncludes 9 patients with neurodevelopmental disorders who have also been diagnosed with cancer bIncludes patients without a personal history of neurodevelopmental disorders or cancer at the tissue of the last clinical visit and/or follow-up. cIncludes trichilemmoma, acral keratosis, papillomatous papules, and genital lentiginosis (penile freckling in males). dIncludes breast fibroadenoma, fibrocystic breast disease, breast papilloma, breast hamartoma, atypical ductal hyperplasia, and typical ductal hyperplasia. eIncludes thyroid nodules, goiter, and Hashimoto thyroiditis.
Clinically Relevant CNVs in Patients with PHTS - The inventors identified 3 of 309 patients with PHTS (1.07%) and pathogenic and/or likely pathogenic CNVs affecting genes associated with PTEN-related cancers or other inherited cancer syndromes according to the American College of Medical Genetics and Genomics guidelines. These included 2 BMPR1A (OMIM 601299) deletions and 1 BRCA1 (OMIM 113705) deletion. The inventors could not ascertain cancer diagnoses because all 3 CNV carriers were children or young adults (aged 3, 6, and 21 years) without a personal history of cancer at the time of consent. The 2 patients with PHTS and BMPR1A deletions upstream of their individual PTEN deletion had juvenile polyposis, as is often observed in chromosome 10q23 microdeletions involving both genes (OMIM 612242). Notably, no pathogenic and/or likely pathogenic CNVs involving known cancer-associated genes were identified among patients in the subset with cancer.
- Pathogenic and/or likely pathogenic CNVs involving genes implicated in the etiology of idiopathic non-syndromic and syndromic ASD/developmental delay and/or neurodevelopmental disorders as well as known pathogenic CNVs associated with ASD, developmental delay, and neurodevelopmental disorders were then investigated. The inventors found 11 of 110 patients in the ASD/DD group (10.0%) harbored such pathogenic and/or likely pathogenic CNVs, compared with 5 of 194 patients in the no ASD/DD group (2.6%) (OR, 4.2; 95% CI, 1.4-13.7; P=0.008) and 2 of 121 (1.7%) patients in the subset with cancer (OR, 6.6; 95% CI, 1.6-44.5; P=0.007) (
FIG. 2 ). The CNV carriers included 10 male and 6 female patients with PHTS (mean [SD] age at consent, 22 [22.1] years). The CNVs included genomic loci associated with other genomic syndromes with overlapping clinical features, such as chromosome 8p23.1 duplication syndrome and chromosome 1q21.1 thrombocytopenia-absent radius syndrome. - The present study evaluated the association of CNVs with clinical outcomes, specifically cancer vs ASD/DD, in individuals with germline pathogenic PTEN mutations. The inventors found that patients with PHTS and ASD/DD have an overall increased genome-wide CNV burden per individual and an enrichment of clinically relevant CNVs when compared with the subset of patients with cancer and those without ASD/DD. These data provide proof that CNVs may act as genomic modifiers of disease risk in phenotypically heterogeneous hereditary disorders such as PHTS.
- As many as 23% of patients with PHTS develop ASD/DD. Conversely, 2% to 5% of unselected patients with ASD/DD and as many as 50% of children with ASD and macrocephaly have been found to carry germline PTEN mutations. Hansen-Kiss et al., J Med Genet., 54(7):471-478 (2017). As such, PTEN itself is a syndromic autism gene with well-established roles in nervous system development and neuronal function. Tilot et al., Neurotherapeutics, 12(3):609-619 (2015). However, why more than 75% of PTEN mutation carriers do not develop ASD/DD remains a clinical conundrum. These findings suggest pathogenic and likely pathogenic CNVs are associated with ASD/DD risk regardless of the particular coexisting germline PTEN mutation. Autism spectrum disorder is believed to be a highly heritable disorder, with complex genetic and biological basis. Pathogenic CNVs have been identified in 8% to 21% of individuals with idiopathic ASD, with higher frequencies reported in more severe cases, including causing syndromic ASD. Schaefer et al., Genet Med., 15(5):399-407 (2013). Notably, particular pathogenic CNVs have also been identified in neurotypical control individuals, including unaffected family members, albeit with significantly lower frequencies. Heil K M, Schaaf C P., Curr Psychiatry Rep., 15(1):334 (2013). First, this observation corroborates the incomplete penetrance and extreme variability in expression of the associated CNVs, meaning that not all carriers will manifest the associated clinical features. Second, this observation supports the burgeoning hypothesis that ASD etiology and severity are modulated through additive effects of multiple genomic aberrations, the so-called 2-hit (or multiple-hit) model. Demily et al., J Autism Dev Disord., 48(8):2886-2889 (2018). These characteristics are highly relevant in the context of modifiers within an inherently predisposed genetic background. In the case of PHTS, the inventors found evidence for the association of pathogenic CNVs with the coexisting germline PTEN mutations to favor ASD/DD clinical outcomes.
- For example, CNVs involving CYFIP1 were identified in 3 unrelated patients with PHTS in the ASD/DD group. CYFIP1 encodes cytoplasmic FMR1-interacting
protein 1, a protein originally found to interact with fragile X mental retardation protein. Increased CYFIP1 dosage has been shown to cause aberrant neuronal cellular and dendritic morphologic features and to be associated with ASD in humans and murine model organisms. Noroozi et al., Metab Brain Dis., 33(4):1353-1358 (2018). Importantly, CYFIP1 expression was inversely correlated with PTEN expression levels, with concomitant dysregulation of mammalian target of rapamycin (mTOR) signaling, suggesting that such CNVs may represent a second hit for patients with PHTS already harboring deleterious PTEN mutations that upregulate AKT-mTOR signaling. In cases of CYFIP1 duplications, decreased PTEN protein levels could also affect wild-type PTEN. In the context of CYFIP1 deletion, as was observed for 1 of the 3 patients with PHTS and CNVs involving CYFIP1 in this study, increased levels of a mutant PTEN protein may result in dominant negative effects (Papa et al., Cell, 157(3):595-610 (2014)), inhibiting wild-type PTEN and hence exacerbating the condition. - Notwithstanding the association of CNVs with multiple neurodevelopmental disorders, CNVs have also been implicated in the etiology of neuropsychiatric diseases such as epilepsy, schizophrenia, and bipolar disorder. Merikangas et al., Trends Genet., 25(12):536-544 (2009). A broad spectrum of neuropsychiatric phenotypes has been observed in patients with PHTS ranging from normal development and intelligence to severely debilitating neurocognitive and motor aberrations, including generalized anxiety, adult-onset movement disorders, obsessive-compulsive disorder, and psychosis. Whether particular CNVs affect the spectrum or severity of such motor and/or neurocognitive disease manifestations in PHTS warrants further scrutiny in larger independent prospective series.
- The identification of testable clinically relevant genomic modifiers in PHTS is important for risk stratification and serves as proof of principle for other phenotypically variable disorders. Patients with PHTS and ASD/DD have an increased burden of pathogenic and/or likely pathogenic CNVs associated with neurodevelopmental disorders. Although CNV analysis is indicated as a first-tier clinical diagnostic test for patients with unexplained ASD/DD, it is not standard to test for such genomic alterations in the setting of an established diagnosis with a syndromic high-penetrance mendelian gene such as PTEN. Copy number variation analysis on immediate identification of germline PTEN mutation in infants and children may be beneficial. The presence of pathogenic and/or likely pathogenic CNVs in PHTS would suggest high likelihood of ASD/neurodevelopmental delay, leading to timely referral to formal evaluation and, if the results are positive, subsequent therapy. The earlier such interventions are instituted, the better the outcomes
- The complete disclosure of all patents, patent applications, and publications, and electronically available material cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/128,446 US20210190769A1 (en) | 2019-12-20 | 2020-12-21 | Distinguishing cancer from neurological risk using copy number variation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962951518P | 2019-12-20 | 2019-12-20 | |
US17/128,446 US20210190769A1 (en) | 2019-12-20 | 2020-12-21 | Distinguishing cancer from neurological risk using copy number variation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210190769A1 true US20210190769A1 (en) | 2021-06-24 |
Family
ID=74104252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/128,446 Pending US20210190769A1 (en) | 2019-12-20 | 2020-12-21 | Distinguishing cancer from neurological risk using copy number variation |
Country Status (1)
Country | Link |
---|---|
US (1) | US20210190769A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
-
2020
- 2020-12-21 US US17/128,446 patent/US20210190769A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030092019A1 (en) * | 2001-01-09 | 2003-05-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia |
Non-Patent Citations (15)
Title |
---|
, Ioannidis (Nature Genetics, Vol. 29, pages 306-309, November 2001) * |
Benner et al (Trends in Genetics (2001) volume 17, pages 414-418) * |
Chung (Journal of the Formosan Medical AssociationVolume 113, Issue 7, July 2014, Pages 400-408 . * |
Cooper (Detection of Copy Number Variation Using SNP Genotyping, Human Pluripotent Stem Cells: Methods and Protocols, (2011) pages 243-252) * |
Frazier (Molecular Psychiatry (2015) 20, 1132–1138) * |
Hagerman (Pediatrics. 2009 January ; 123(1): 378–390. doi:10.1542/peds.2008-0317).. * |
Hegele (Arterioscler Thromb Vasc Biol. 2002;22:1058-1061) * |
Hirschhorn et al. (Genetics in Medicine. Vol. 4, No. 2, pages 45-61, March 2002) * |
Landrum (NucleicAcidsResearch,2016,Vol.44,Data base issue Published online17November2015 doi:10.1093/nar/gkv1222).. * |
Leeneer (Breast Cancer Res Treat (2012) 132:87–95) * |
Lopez (CANCER GENOMICS & PROTEOMICS 15: 115-120 (2018)) * |
Lucentini J. (The Scientist (Dec. 20, 2004), page 20) * |
May et al (Science (1988) volume 241, page 1441) * |
Nelen (Human Molecular Genetics, 1997, Vol. 6, No. 8 1383-1387) * |
Ngeow (Clin Oncol 32:1818-1824 (2014)) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smeland et al. | The polygenic architecture of schizophrenia—rethinking pathogenesis and nosology | |
Westenberger et al. | A hexanucleotide repeat modifies expressivity of X‐linked dystonia parkinsonism | |
Legrand et al. | Mutation spectrum in the ABCC6 gene and genotype–phenotype correlations in a French cohort with pseudoxanthoma elasticum | |
Singh et al. | Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders | |
Matoba et al. | Common genetic risk variants identified in the SPARK cohort support DDHD2 as a candidate risk gene for autism | |
McNaughton et al. | Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series | |
Brouwers et al. | Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites | |
Maestrini et al. | High-density SNP association study and copy number variation analysis of the AUTS1 and AUTS5 loci implicate the IMMP2L–DOCK4 gene region in autism susceptibility | |
Ylisaukko-oja et al. | Analysis of four neuroligin genes as candidates for autism | |
Bacchelli et al. | An integrated analysis of rare CNV and exome variation in Autism Spectrum Disorder using the Infinium PsychArray | |
Lind et al. | Dyslexia and DCDC2: normal variation in reading and spelling is associated with DCDC2 polymorphisms in an Australian population sample | |
Momosaki et al. | Newborn screening for Pompe disease in Japan: report and literature review of mutations in the GAA gene in Japanese and Asian patients | |
Toma et al. | An examination of multiple classes of rare variants in extended families with bipolar disorder | |
Blair et al. | Positional cloning, association analysis and expression studies provide convergent evidence that the cadherin gene FAT contains a bipolar disorder susceptibility allele | |
Xie et al. | DNA methylation and tag SNPs of the BDNF gene in conversion of amnestic mild cognitive impairment into Alzheimer’s disease: a cross-sectional cohort study | |
US20210212960A1 (en) | Identification of seizure susceptibility region in wolf-hirschhorn syndrome and treatment thereof | |
Zhang et al. | Follow‐up study of 25 Chinese children with PLA 2G6‐associated neurodegeneration | |
Hiraide et al. | Genetic and phenotypic analysis of 101 patients with developmental delay or intellectual disability using whole‐exome sequencing | |
Chang et al. | Novel PKD1 and PKD2 mutations in Taiwanese patients with autosomal dominant polycystic kidney disease | |
Cellini et al. | Multiple genomic copy number variants associated with periventricular nodular heterotopia indicate extreme genetic heterogeneity | |
Fu et al. | Somatic mosaicism and variant frequency detected by next-generation sequencing in X-linked Alport syndrome | |
US20140342919A1 (en) | Markers related to age-related macular degeneration and uses therefor | |
Peces et al. | Severe congenital nephrogenic diabetes insipidus in a compound heterozygote with a new large deletion of the AQP2 gene. A case report | |
Svob Strac et al. | The association between HTR1B gene rs13212041 polymorphism and onset of alcohol abuse | |
Gill | Developmental psychopathology: The role of structural variation in the genome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
AS | Assignment |
Owner name: THE CLEVELAND CLINIC FOUNDATION, OHIO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ENG, CHARIS;LAL, DENNIS;SIGNING DATES FROM 20210211 TO 20210518;REEL/FRAME:056310/0411 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:CLEVELAND CLINIC FOUNDATION;REEL/FRAME:065380/0273 Effective date: 20201221 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |